NEURO61

Session information

Print

Symposium

[S-39] Symposium 39
The concept of MOG-IgG positive diseases

Tue. Sep 1, 2020 4:00 PM - 5:30 PM Room 6 (OKAYAMA CONVENTION CENTER 2F Reception Hall)

Chair：IchiroNakashima（Department of Neurology, Tohoku Medical and Pharmaceutical University）,TatsuroMisu（Department of Neurology, Tohoku University）

[S-39-1] MOG-IgG assays and their clinical associations in children

○Patrick Waters (University of Oxford, UK)

Auto-antibodies (IgG) against myelin oligodendrocyte glycoprotein (MOG) are detected in the serum of patients with various demyelinating diseases. These patients are known to show repeated clinical episodes of inflammatory demyelinating attacks in the central nervous system. Although the associated pathogenicity and mechanism of inflammatory demyelination remains inconclusive, it is known that patients with MOG-IgG have a different clinical spectrum from those with other demyelinating diseases, such as multiple sclerosis. We conducted this symposium to understand the clinical features and the spectrum of MOG-IgG related demyelinating diseases.

[S-39-2] Clinical manifestation of MOG-IgG associated encephalomyelitis

○Sung Min Kim (Seoul National University Hospital, Korea)

Auto-antibodies (IgG) against myelin oligodendrocyte glycoprotein (MOG) are detected in the serum of patients with various demyelinating diseases. These patients are known to show repeated clinical episodes of inflammatory demyelinating attacks in the central nervous system. Although the associated pathogenicity and mechanism of inflammatory demyelination remains inconclusive, it is known that patients with MOG-IgG have a different clinical spectrum from those with other demyelinating diseases, such as multiple sclerosis. We conducted this symposium to understand the clinical features and the spectrum of MOG-IgG related demyelinating diseases.

[S-39-3] Immunological features of MOG-IgG diseases

○Kimihiko Kaneko1,2 (1.Department of Neurology, NHO Miyagi National Hospital, Japan, 2.Department of Neurology, Tohoku University, Japan)

Auto-antibodies (IgG) against myelin oligodendrocyte glycoprotein (MOG) are detected in the serum of patients with various demyelinating diseases. These patients are known to show repeated clinical episodes of inflammatory demyelinating attacks in the central nervous system. Although the associated pathogenicity and mechanism of inflammatory demyelination remains inconclusive, it is known that patients with MOG-IgG have a different clinical spectrum from those with other demyelinating diseases, such as multiple sclerosis. We conducted this symposium to understand the clinical features and the spectrum of MOG-IgG related demyelinating diseases.

[S-39-4] Pathology of MOG-IgG diseases

○Yoshiki Takai1, Tatsuro Misu1, Kazuo Fujihara1,2, Masashi Aoki1 (1.Department of Neurology, Tohoku University Hospital, Japan, 2.Department of Multiple Sclerosis Therapeutics, Fukushima Medical University, Japan)

Auto-antibodies (IgG) against myelin oligodendrocyte glycoprotein (MOG) are detected in the serum of patients with various demyelinating diseases. These patients are known to show repeated clinical episodes of inflammatory demyelinating attacks in the central nervous system. Although the associated pathogenicity and mechanism of inflammatory demyelination remains inconclusive, it is known that patients with MOG-IgG have a different clinical spectrum from those with other demyelinating diseases, such as multiple sclerosis. We conducted this symposium to understand the clinical features and the spectrum of MOG-IgG related demyelinating diseases.

[S-39-5] Pediatric cases of MOG-IgG disease

○Takahiro Ikeda, Takanori Yamagata (Department of Pediatrics, Jichi Medical University, Japan)

Auto-antibodies (IgG) against myelin oligodendrocyte glycoprotein (MOG) are detected in the serum of patients with various demyelinating diseases. These patients are known to show repeated clinical episodes of inflammatory demyelinating attacks in the central nervous system. Although the associated pathogenicity and mechanism of inflammatory demyelination remains inconclusive, it is known that patients with MOG-IgG have a different clinical spectrum from those with other demyelinating diseases, such as multiple sclerosis. We conducted this symposium to understand the clinical features and the spectrum of MOG-IgG related demyelinating diseases.